Elvitegravir is an antiretroviral agent used in combination with other antiretrovirals for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection.
- Mechanism
- Curator reviewed
Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Integrase is an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human topoisomerases I or II.
- Primary indication
- Elvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.Curator reviewed · 2 structured indications
- Formula / weight
- C23H23ClFNO5 · 447.884 g/mol (avg)
- First approval
- Canada, 2012 · United States, 2012 · European Union, 2016
- Code names
- GS-9137 · JTK-303
- Brand names
Resolves to
JUZYLCPPVHEVSV-LJQANCHMSA-NSMILES[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Elvitegravir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account